Zhende Medical(603301)2023-04-25 16:00Financial Performance - The company's operating revenue for 2022 reached CNY 6,137,634,431.69, representing a year-on-year increase of 20.54% compared to CNY 5,091,572,447.78 in 2021[23]. - The net profit attributable to shareholders of the listed company was CNY 703,226,016.47, a significant increase of 40.09% from CNY 501,983,606.77 in the previous year[23]. - The net cash flow from operating activities increased by 52.40% to CNY 1,246,045,055.93, compared to CNY 817,629,318.83 in 2021[23]. - Total assets at the end of 2022 amounted to CNY 7,896,933,885.12, reflecting a growth of 22.97% from CNY 6,421,676,690.51 at the end of 2021[24]. - The company reported a net asset attributable to shareholders of CNY 5,541,678,060.39, which is a 36.27% increase from CNY 4,066,740,693.18 at the end of 2021[24]. - Basic earnings per share for 2022 increased by 8.71% to CNY 2.87 compared to CNY 2.64 in 2021[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 33.18% to CNY 2.97 per share in 2022 from CNY 2.23 in 2021[25]. - The gross profit margin was 35.00%, a decrease of 0.95% compared to the previous year, primarily due to the price normalization of isolation protective products[75]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of CNY 7.50 per 10 shares (including tax), totaling CNY 199,741,320 based on 266,321,760 shares[6]. - The total cash dividend amount (including tax) is CNY 312,857,887.89, which accounts for 45.93% of the net profit attributable to ordinary shareholders[182]. - The company emphasizes continuous and stable cash dividends to enhance long-term investment returns for shareholders[178]. - The cash dividend proposal is subject to approval at the 2022 annual general meeting[179]. Market and Business Expansion - The company achieved a main business revenue of 6.131 billion yuan, a year-on-year increase of 24.94%, with net profit attributable to shareholders reaching 681 million yuan, up 14.31%[37]. - Domestic main business revenue reached 4.104 billion yuan, a year-on-year increase of 90.62%, with hospital line revenue at 2.713 billion yuan, excluding isolation protective products[39]. - The company expanded its coverage to over 7,000 hospitals nationwide, an increase of nearly 1,000 hospitals compared to the beginning of the reporting period, including over 1,000 top-tier hospitals[38]. - The company’s international main business revenue was 2.027 billion yuan, a decrease of 26.40% year-on-year, primarily due to high sales of isolation protective products in the previous year[41]. - The company is focused on solidifying its management foundation and improving economic efficiency amid a complex external environment[36]. Research and Development - Research and development expenses increased by 48.23% to 227 million RMB, indicating a strong commitment to innovation[72]. - The company emphasized R&D investment, establishing a medical device industry innovation consortium to enhance technical innovation capabilities[43]. - The company has established a mechanism for intellectual property protection in the pharmaceutical procurement sector, indicating a strategic focus on compliance and innovation[104]. - The company is committed to investing in R&D, focusing on key technologies in infection control and wound care, and exploring sustainable materials for product development[129]. Acquisitions and Investments - The company acquired 100% equity of MIDMEDS LIMITED in the UK, expanding its channel coverage and enhancing its product portfolio in surgical infection control[49]. - The company completed a capital increase of 137.06 million RMB in its wholly-owned subsidiary, Shaoxing Zhend Medical Supplies Co., Ltd., maintaining 100% control[108]. - The company invested 100 million RMB in Anhui Meidis, also retaining 100% control post-capital increase[109]. - The company plans to acquire 100% equity of Jiangsu Yinbeisi Technology Development Co., Ltd. for 24.33 million Yuan, focusing on pre-filled catheter flushing products[137]. Governance and Compliance - The company’s governance practices comply with relevant laws and regulations, with no significant discrepancies noted[143]. - The company has established a comprehensive governance structure to enhance investor relations and protect minority shareholders' rights[197]. - The company has implemented measures to ensure the independence of its assets, personnel, and operations[143]. - The company’s financial resolutions and proposals for related party transactions were also approved during the annual meeting[146]. Employee and Organizational Development - The total number of employees in the parent company is 1,524, while the total number of employees in major subsidiaries is 6,961, resulting in a combined total of 8,485 employees[172]. - The company has established a competitive compensation policy that includes basic salary, performance assessment, and bonus incentives, focusing on employee performance and contributions[174]. - The company has implemented a comprehensive training program to enhance employee skills and organizational capabilities[175]. Environmental and Social Responsibility - The company has implemented internal environmental management systems, including water pollution prevention and solid waste management[194]. - The company emphasizes energy conservation and pollution reduction as part of its sustainable development strategy[197]. - The company actively participates in social responsibility initiatives, including donations of medical supplies[197].